Form 10-Q Vaxcyte, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX)
November 6, 2024 5:59 AM ESTLeerink Partners analyst David Risinger reiterated an Outperform rating and $135.00 price target on Vaxcyte (NASDAQ: PCVX).
The analyst comments "Bottom Line: PCVX reported OpEx of $140M which was +2% or +$3M vs. our est. of $137M. The companys pipeline remains on track; the next readout to watch is VAX-24 Ph2 infant data at the end of 1Q25. We remain bullish on PCVX following competitive PCV pipeline commentary from PFE (MP) and GSK (Not Rated). PFE disclosed on its on... More
